Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.74 |
| ▸ | SRC | P12931 | 6/20 | 0.74 |
| ▸ | RET | P07949 | 3/20 | 0.74 |
| ▸ | JAK2 | O60674 | 2/20 | 0.74 |
| ▸ | DYRK3 | O43781 | 2/20 | 0.74 |
| ▸ | CDK1 | P06493 | 2/20 | 0.74 |
| ▸ | ROS1 | P08922 | 2/20 | 0.74 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.74 |
| ▸ | CDK2 | P24941 | 2/20 | 0.74 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.74 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.74 |
| ▸ | CLK2 | P49760 | 2/20 | 0.74 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.74 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.74 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.74 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.74 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.74 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.74 |
| ▸ | CDC7 | O00311 | 1/20 | 0.74 |
| ▸ | PLK4 | O00444 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22243341 | 1.00 | KDR (0.74) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL22243320 | 0.92 | KDR (0.87) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL401336 | 0.89 | KDR (0.77) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL30321053 | 0.89 | KDR (0.77) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL12422280 | 0.88 | KDR (0.80) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL22243295 | 0.87 | KDR (0.56) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL29590269 | 0.86 | SRC (0.77) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL1318717 | 0.86 | SRC (0.77) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL6109045 | 0.85 | KDR (1.00) | KDRSRCRETJAK2DYRK3 | |
| SCHEMBL6109435 | 0.85 | KDR (1.00) | KDRSRCRETJAK2DYRK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179027-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | SHENZHEN TARGETRX, INC. (CN) | 2025-06-05 | — | — | US | disclosed |
| EP-4474377-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | Shenzhen TargetRx, Inc. (CN) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023165570-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2023-09-07 | — | — | WO | disclosed |
| CN-116693458-A | Cycloalkyl or heterocyclyl substituted heteroaryl compounds, compositions and uses thereof | 深圳市塔吉瑞生物医药有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-116589465-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-113710671-B | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2023-04-28 | — | — | CN | disclosed |
| CN-113710671-A | Cyclic molecules as inhibitors of bruton's tyrosine kinase | 明慧医药（上海）有限公司 | 2021-11-26 | — | — | CN | disclosed |
| EP-3912980-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | Minghui Pharmaceutical (Shanghai) Limited (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020147798-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITOR | 明慧医药（上海）有限公司 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179027-A1 | CYCLOALKYL OR HETEROCYCLYL SUBSTITUTED HETEROARYL COMPOUND, AND COMPOSITION AND USE THEREOF | BTK, LYN, SYK | KDR 852/4885SRC 7/4885RET 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.